From the Department of Neurology (M.W.R., J.U., E.B.) and Division of Medical Oncology (M.W.R., J.U.), Mayo Clinic, Rochester, MN.
Neurology. 2019 Mar 19;92(12):568-574. doi: 10.1212/WNL.0000000000007126. Epub 2019 Feb 13.
The field of neuro-oncology has recently experienced a renaissance in the understanding of the molecular underpinnings and pathophysiology of glioma. Genetic markers have significant implications regarding treatment responsiveness and prognosis and are now the primary basis for classification. This article gives an updated understanding of the pathogenesis and mechanisms of resistance of glioma via discussion of 4 molecular and genetic markers: MGMT, , 1p/19q, and .
神经肿瘤学领域最近在理解胶质瘤的分子基础和病理生理学方面经历了一次复兴。遗传标志物对治疗反应和预后有重要意义，现在是分类的主要依据。本文通过讨论 4 个分子和遗传标志物：MGMT、IDH、1p/19q 和 TERT，阐述了胶质瘤的发病机制和耐药机制，从而对其有了更深入的了解。
